WEIFANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it will issue financial results for the first quarter fiscal year 2010 (three months ended September 30, 2009) after the close of the stock market on Monday, November 16, 2009. Management will conduct a conference call on Tuesday, November 17, 2009 at 8:00 A.M. Eastern Standard Time to discuss these results. A question and answer session will follow management's presentation. Ms. Yiru Melody Shi (CFO), and Ms. Shenglian Iris Wang (Investor Relations Assistant Manager) will be the primary speakers on the call. To participate, please call the following numbers ten minutes before the call start time: Phone Number: + 1 (877) 407-8035 (North America) Phone Number: + 1 (201) 689-8035 (International) A replay of the call will be available through Tuesday, November 24, 2009, at 11:59 P.M. Eastern Standard Time. For the replay, please call: Phone Number: +1 (877) 660-6853 (North America) Phone Number: +1 (201) 612-7415 (International) Account Number: 286 Conference ID Number: 337862 About Shengtai Pharmaceutical, Inc. Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes. It also manufactures and supplies glucose and cornstarch products to the food, beverage and industrial production industries in China. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com/ . Forward Looking Statements Certain statements in this press release and oral statements made by the Company constitute forward-looking statements concerning the Company's business and products. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, the Company's planned capacity expansion and predictions and guidance relating to the Company's future financial performance. We have based these forward- looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large- scale implementation of the Company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations. For further information, please contact: Shengtai Pharmaceutical, Inc. Ms. Yiru Melody Shi Chief Financial Officer Tel: +1-949-468-7078 Email: Ms. Shenglian Iris Wang Investor Relations Assistant Manager Tel: +86-536-6295802 Email: DATASOURCE: Shengtai Pharmaceutical, Inc. CONTACT: Shengtai Pharmaceutical, Inc., Ms. Yiru Melody Shi, Chief Financial Officer, +1-949-468-7078, and Ms. Shenglian Iris Wang, Investor Relations Assistant Manager, +86-536-6295802, Web site: http://www.shengtaipharmaceutical.com/

Copyright